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MaBACKGROUND Aspirin administration, as part of a dual antiplatelet treatment regimen, is essential for patients
undergoing percutaneous coronary intervention (PCI). Although the correlation between high on-clopidogrel treatment
platelet reactivity (HCPR) and clinical outcome is well established, data for high on-aspirin treatment platelet reactivity
(HAPR) are conﬂicting.
OBJECTIVES The aim of the ISAR-ASPI (Intracoronary Stenting and Antithrombotic Regimen—ASpirin and Platelet
Inhibition) registry was to assess the value of HAPR as a possible prognostic biomarker in PCI-treated patients with regard
to clinical outcome.
METHODS From February 2007 to May 2013, we identiﬁed 7,090 consecutive PCI-treated patients with measured
on-aspirin treatment platelet aggregation values directly before PCI. Platelet function was assessed with a Multiplate
analyzer. The primary endpoint was death or stent thrombosis (ST) at 1 year.
RESULTS Theupperquintile ofpatients (n¼ 1,414), according toMultiplatemeasurements,wasdeﬁnedas theHAPRcohort.
Compared with non-HAPR patients (n ¼ 5,676), HAPR patients showed a signiﬁcantly higher risk of death or ST at 1 year
(6.2% vs. 3.7%, respectively; odds ratio [OR]: 1.78; 95%conﬁdence interval [CI]: 1.39 to 2.27; p<0.0001). HAPRwas found
to be an independent predictor of the primary outcome (adjusted hazard ratio [HRadj]: 1.46; 95%CI: 1.12 to 1.89; p¼0.005).
CONCLUSIONS HAPR, measured at the time point of the PCI, is associated with a higher risk for death or ST during the
ﬁrst year after PCI. Present data are in support of the addition of HAPR to a panel of prognostic biomarkers in PCI-treated
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ABBR EV I A T I ON S
AND ACRONYMS
AA = arachidonic acid
ADP = adenosine diphosphate
AU = aggregation units
HAPR = high on-aspirin
treatment platelet reactivity
HCPR = high on-clopidogrel
treatment platelet reactivity
IDI = integrated discrimination
improvement
MACE = major adverse cardiac
event(s)
NRI = net reclassiﬁcation
improvement
NSTEMI = non–ST-segment
elevation myocardial infarction
ST = stent thrombosis
STEMI = ST-segment elevation
myocardial infarction
TIMI = Thrombolysis In
Myocardial Infarction
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864Early studies reported an association be-
tween HAPR and a higher risk for ischemic
events in patients with cardiovascular dis-
ease (2–5), as well as an increased risk for
the occurrence of stent thrombosis (ST) (6–8).
Meta-analyses investigating the issue of
HAPR and clinical outcome arrived at the
same result: there were more cardiovascular
events in patients displaying HAPR (9–11). In
contrast, the recently published results of
the large-scale ADAPT-DES (Assessment of
Dual AntiPlatelet Therapy With Drug Eluting
Stents) trial did not ﬁnd a link between HAPR
and the risk for ischemic events including
ST, myocardial infarction (MI), or death (12).
In contrast to HCPR (1), the term HAPR and
the phenomenon of “aspirin resistance” are
poorly deﬁned in published reports, and its
prevalence varies widely (13–16).SEE PAGE 872In this study, we measured periproce-
dural on-aspirin treatment platelet reactivity to
further stratify PCI-treated patients with regard to
their risk for ischemic events, and the aim of the
ISAR-ASPI (Intracoronary Stenting and Antithrom-
botic Regimen—ASpirin and Platelet Inhibition) reg-
istry was to assess the prognostic value of HAPR in
PCI-treated patients.
METHODS
STUDY POPULATIONS. For the registry, patients un-
dergoing PCI (all Caucasian) in 2 participating centers
(Deutsches Herzzentrum München and I. Medizinische
Klinik, Klinikum rechts der Isar, Technische Universität
München, Munich, Germany) were investigated.
Clinical and outcome data from all patients who
were enrolled in this registry were prospectively
collected. Between February 2007 and May 2013, a total
of 7,090 consecutive patients who were pretreated
with aspirin were analyzed with regard to platelet ag-
gregation data and their clinical outcome (ischemic and
bleeding events). All patients received an intravenous
(IV) dose of 500 mg of aspirin and pretreatment with an
ADP receptor antagonist in preparation for the PCI
procedure. Aspirin, 100 mg twice daily, was recom-
mended for an indeﬁnite period. All other treatments,
such as a dual antiplatelet treatment regimen including
aspirin, were recommended per standard of care.
The availability of a platelet function assessment for
the on-aspirin treatment platelet reactivity obtained
immediately before PCI was part of the inclusionary
criteria. Patients were included in our registry withall clinical presentations, including stable angina,
unstable angina, and ST-segment elevation myocar-
dial infarction (STEMI) or non–ST-segment elevation
myocardial infarction (NSTEMI). Patients with
cardiogenic shock or ST at their index PCI were
excluded from this registry.
BLOOD SAMPLING AND PLATELET FUNCTION
TESTING. Whole blood for platelet function testing
was collected from all patients in 4.5-ml plastic tubes
containing the anticoagulant lepirudin (25 mg/ml)
(Reﬂudan; Dynabyte, Munich, Germany). Along with
the index PCI, blood samples for platelet function
testing were obtained from the arterial sheath of
patients immediately before PCI and after the
administration of 500 mg of aspirin (IV) that was
given a few minutes before PCI. Evidence that a few
minutes’ duration from administration of IV aspirin
to measurement of platelet function is sufﬁcient was
provided earlier by our group (17) and others (18,19),
by showing complete and immediate platelet inhibi-
tion across the thromboxane pathway within 5 min of
IV aspirin administration.
Quantitative determination of platelet function
triggered by arachidonic acid (AA) was assessed
with impedance aggregometry, using the Multiplate
analyzer (Roche Diagnostics, Basel, Switzerland), as
recently described (20). Each Multiplate test cell in-
corporates 2 independent sensor units. One unit con-
sists of 2 silver-coated highly conductive copper wires
with a length of 3.2 mm. After dilution (1:2 with 0.9%
NaCl solution) of lepirudin-anticoagulated whole
blood and stirring for 3 min in the test cuvettes at 37C,
a ﬁnal concentration of AA (0.5 mmol/l) was added.
The increase of impedance due to the attachment of
platelets to the electrodes is continuously recorded
for each sensor unit separately and transformed to
aggregation units (AU) that are plotted against time.
Measurement time is 6 min. Aggregation measured
with multiple electrode aggregometry is quantiﬁed as
area under the curve of AU (AU  min). All materials
used, including AA, were obtained from the manu-
facturer (Roche Diagnostics).
We deﬁned HAPR by setting a cut-off point at the
upper quintile (20%) of platelet aggregation mea-
surements. The primary ischemic outcome measure
was the composite of death from any cause or ST
(deﬁnite or probable ST) at 1 year. Early outcome
data (at 30 days) are presented here as well. We also
assessed the incidence of cardiovascular death and
MI. Cardiovascular death and deﬁnite and probable
ST were deﬁned according to Academic Research
Consortium criteria (21). Hypercholesterolemia, arte-
rial hypertension, and diabetes mellitus were deﬁned
according to World Health Organization guidelines
TABLE 1 Baseline Characteristics of the Patients
ASPI >203
(5th Quintile)
(n ¼ 1,414)
ASPI #203
(1st–4th Quintile)
(n ¼ 5,676) p Value
Age, yrs 68.6  11.3 68.0  10.9 0.08
Female 283 (20) 1,399 (24.6) 0.0002
Body mass index, kg/m2 27.3  4.4 27.6  4.5 0.03
Patients with diabetes mellitus 380 (26.9) 1,608 (28.3) 0.28
Patients with arterial hypertension 818 (57.9) 3302 (58.2) 0.83
Systolic blood pressure, mm Hg 144.8  25.7 148.2  25.4 <0.0001
Active smokers 220 (15.6) 962 (16.9) 0.21
Patients with hypercholesterolemia 1,000 (70.7) 4,256 (74.9) 0.001
LDL cholesterol, mg/dl 105.7  39.2 108.3  41.2 0.03
HDL cholesterol, mg/dl 49.4  15.9 49.9  15.3 0.28
Troponin T, ng/ml 0.17  0.65 0.12  0.63 0.009
Creatinine, mg/dl 1.1  0.4 1.1  0.6 0.85
ADP (AU  min) 371.2  277.3 281  241.8 <0.0001
Taking aspirin at admission 1,290 (91.2) 5,323 (93.8) 0.0006
Taking ADP receptor blocker at admission 943 (66.7) 4,042 (71.2) 0.001
Taking ADP receptor blocker at discharge 0.21
None 6 (0.4) 14 (0.2)
Clopidogrel 1,340 (94.8) 5,396 (95.1)
Prasugrel 61 (4.3) 248 (4.4)
Ticagrelor 6 (0.4) 17 (0.3)
Ticlopidin 1 (0.07) 1 (0.02)
Patients with previous MI 357 (25.3) 1,428 (25.2) 0.95
Patients with previous bypass surgery 197 (13.9) 786 (13.9) 0.93
Patients with coronary artery disease 0.68
1-vessel disease 258 (18.3) 994 (17.5)
2-vessel disease 379 (26.8) 1,493 (26.3)
3-vessel disease 777 (54.9) 3,189 (56.2)
Patients with CAD presentation <0.0001
STEMI 140 (9.9) 523 (9.2)
NSTEMI 137 (9.7) 419 (7.4)
Unstable angina 291 (20.6) 1,453 (25.6)
Stable angina 846 (59.8) 3,281 (57.8)
Values are mean  SD or n (%).
ADP ¼ adenosine diphosphate; ASPI ¼ arachidonic–acid-induced platelet aggregation value on the Multiplate
Analyzer (ASPItest); AU ¼ aggregation unit; CAD ¼ coronary artery disease; HDL ¼ high-density lipoprotein;
LDL ¼ low-density lipoprotein; MI ¼ myocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial
infarction; STEMI ¼ ST-segment elevation myocardial infarction.
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baseline characteristics in Table 1 was the pre-
catheter value within the shortest interval to cathe-
terization. With regard to bleeding, we assessed the
incidence of in-hospital major and minor bleeding
events, deﬁned according to Thrombolysis In Myo-
cardial Infarction (TIMI) criteria. Patients were ex-
pected to stay in the hospital for at least 2 days after
PCI. Discharged patients were interviewed by tele-
phone after 30  7 days and after 1 year. Those pa-
tients with cardiac complaints were seen in the
outpatient clinic for complete clinical, electrocardio-
graphic, and laboratory check-up. ISAR study center
personnel collected patient data and prospectively
entered them into a computer database. All possible
information from referring physicians, relatives, and
hospital readmissions were entered. Source docu-
ments were checked to ensure high-quality data.
STATISTICAL ANALYSIS. Variables are mean  SD,
counts (percentages), and median with interquartile
range. Kolmogorov-Smirnov test was used to test for
normal distribution of continuous data. Platelet
function data were not normally distributed, and
dependent data were compared with 2-sided Wil-
coxon test. Categorical variables were compared using
chi-square test, and normally distributed variables
were compared using the 2-sided Student t test.
Survival analyseswere performed by using the Kaplan-
Meier method, and the differences between groups
were assessed by the log-rank test and the calculation
of odds ratios (ORs) (95% conﬁdence intervals [CIs])
associated with the 30-day and 1-year rates of outcome
of interest. For 1-year outcome data, a Cox propor-
tional hazards model was used to assess the indepen-
dent association between HAPR and death or ST by
calculating adjusted hazard ratios (HR) with 95% CI.
All variables in Table 1 were entered into the Cox
model together with HAPR. Propensity score match-
ing analysis was used to select an equal number of
non-HAPR patients (n ¼ 1,414) who matched the
HAPR patient cohort with regard to variables shown
in Online Table S2. The discriminatory power of the
model regarding death or ST risk with and without
inclusion of HAPR was assessed by calculating the
c-statistics as well as the integrated discrimination
improvement (IDI) and the net reclassiﬁcation impro-
vement (NRI) according to Pencina et al. (22). For both
c-statistic and NRI, the R software library “Hmisc” of
Harrell (without categories) was used (23,24).
For all statistical analyses, a p value of <0.05 was
considered signiﬁcant. All analyses were performed
using R software package (R Statistical Software,
Foundation for Statistical Computing, Vienna,
Austria).RESULTS
Figure 1 provides an overview of patients included
in the ISAR-ASPI registry. The baseline characteristics
of the HAPR and non-HAPR cohorts are shown
in Table 1. The 2 cohorts differed with regard to a
number of baseline characteristics (Table 1). Patients
with HAPR were more often men and showed hy-
percholesterolemia less often; had lower body mass
index, low-density lipoprotein cholesterol concen-
trations, and systolic blood pressure, as well as
higher troponin and ADP values at admission than
non-HAPR patients. Additionally, non-HAPR patients
more often had aspirin and ADP receptor blocker in
their medication regimens at admission. The per-
centage of aspirin at admission was 91.2% in HAPR
PCI (02/2007 to 05/2013)
Pre-treatment: Aspirin 500 mg (n = 9,700)
Platelet function testing available 
No 
ST excluded 
ISAR-ASPI registry
Cardiogenic 
shock excluded 
Yes
(n = 11,588)
(n = 2,450)
(n = 24)
(n = 136)
(n = 7,090)
(n = 7,250)
FIGURE 1 Flow Chart of the Study Registry
Treatmentof patients in the ISAR-ASPI registry. PCI¼ percutaneous
coronary intervention; ST ¼ stent thrombosis.
TABLE 2 Angiograph
Target vessels
Left main coronary a
Left anterior descend
Left circumﬂex coron
Right coronary artery
Venous bypass graft
Complex (type B2 or C
Chronic occlusions
Ostial lesions
Bifurcation lesions
Type of intervention
Placement of drug-e
Placement of bare-m
Balloon angioplasty
Values are n (%). Lesion-re
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(p ¼ 0.0006). The percentage of ADP receptor blocker
at admission was 66.7% in HAPR patients compared
to 71.2% in non-HAPR patients (p ¼ 0.001). Further
details about the type of ADP receptor blockeric and Procedural Characteristics
ASPI >203
(5th Quintile)
(n ¼ 2,509)
ASPI #203
(1st–4th Quintile)
(n ¼ 9,990) p Value
0.59
rtery 118 (4.7) 485 (4.9)
ing coronary artery 1,047 (41.7) 4,111 (41.2)
ary artery 630 (25.1) 2,444 (24.5)
671 (26.7) 2,734 (27.4)
43 (1.7) 216 (2.2)
) lesions 1,941 (77.4) 7,690 (76.9) 0.68
168 (6.7) 689 (6.9) 0.72
619 (24.7) 2,404 (24.1) 0.53
784 (31.2) 3,048 (30.5) 0.47
0.06
luting stent 2,368 (94.4) 9,377 (93.9)
etal stent 26 (1.0) 71 (0.7)
115 (4.6) 542 (5.4)
lated angiographic and procedural characteristics of the patients are shown.administered at discharge are provided in Table 1.
Of note, the proportion of patients with STEMI and
NSTEMI at presentation was higher in patients with
HAPR than in non-HAPR patients, whereas the pro-
portion of patients with stable and unstable angina
was higher in non-HAPR patients. Detailed informa-
tion for angiographic and procedural characteristics
of both study cohorts is shown in Table 2. The dis-
tribution of these characteristics was well balanced
between the 2 cohorts. The majority of lesions (94%)
were treated with a drug-eluting stent (DES) during
the index procedure.
According to propensity matching analysis, 1,414
HAPR patients and 1,414 non-HAPR patients matched
for variables displayed in Online Table S2 were
identiﬁed. Baseline characteristics of propensity
score-matched cohorts are shown in Online Table S2.
ON-ASPIRIN TREATMENT PLATELET AGGREGATION.
The median (interquartile range) AA-induced platelet
aggregation of patients in the ISAR-ASPI registry was
115 (52 to 179) AU min. The upper quintile of platelet
aggregation values was deﬁned as HAPR, corre-
sponding to a cut-off value of 203 AU  min. Patients
with an AA-induced platelet aggregation value of#203
AU  min are referred to as non-HAPR (n ¼ 5,676) pa-
tients, and those with values >203 are referred to as
HAPR patients (n ¼ 1,414). Figure 2 shows the distri-
bution of platelet reactivity measurements observed
after stimulation with AA, following loading with a
single high-loading dose of 500 mg aspirin.
CLINICAL OUTCOME. The incidence of in-hospital
bleeding events (TIMI major and minor) in the HAPR
patients was not signiﬁcantly different from that in
the non-HAPR cohort (95 bleeding events [6.7%] in
the HAPR cohort vs. 324 bleeding events [5.7%] in the
non-HAPR cohort; p ¼ 0.15). The 30-day outcome data
for all ischemic endpoints under investigation are
shown in Table 3.
The incidence of the primary outcome (incidence
of 1-year death or ST) was signiﬁcantly higher in the
HAPR cohort than in the non-HAPR cohort (88 events
[6.2%] vs. 208 events [3.7%]; OR: 1.78, 95% CI: 1.39
to 2.27; p < 0.0001). Figure 3 shows a comparison
between the cumulative incidence of the primary
outcome during 1-year follow-up in the HAPR versus
that in the non-HAPR cohort. The risk for 1-year ST
(deﬁnite or probable) was signiﬁcantly higher in the
HAPR than in the non-HAPR cohort of patients (16 STs
[1.1%] vs. 35 STs [0.6%]; OR: 1.88; 95% CI: 1.05 to 3.37;
p ¼ 0.03) (Figure 4). The incidence of cardiovascular
death was 4.2% in HAPR versus 1.9% in non-HAPR
patients (OR: 2.27; 95% CI: 1.67 to 3.09; p < 0.0001).
Table 4 shows a comparison between the entire
TABLE 3 Clinical Outcome at 30 Days
Event
ASPI >203
(5th Quintile)
(n ¼ 1,414)
ASPI #203
(1st–4th Quintile)
(n ¼ 5,676) OR (95% CI) p Value
Primary endpoint
Death or ST deﬁnite or
ST probable
35 (2.5) 63 (1.1) 2.24 (1.50–3.36) <0.0001
Secondary endpoints
ST deﬁnite or probable 12 (0.8) 20 (0.4) 2.42 (1.21–4.84) 0.012
ST deﬁnite 9 (0.6) 17 (0.3) 2.14 (0.97–4.70) 0.06
ST probable 3 (0.2) 3 (0.05) 4.05 (0.92–17.7) 0.06
All–cause death 30 (2.1) 50 (0.9) 2.43 (1.56–3.76) <0.0001
Cardiovascular death 24 (1.7) 37 (0.7) 2.62 (1.59–4.29) 0.0001
Myocardial infarction 38 (2.7) 121 (2.1) 1.26 (0.88–1.82) 0.21
Death or MI 59 (4.2) 157 (2.8) 1.51 (1.13–2.04) 0.006
Values are n (%). Ischemic clinical outcome data in the HAPR (ASPI >203) and non-HAPR (ASPI#203) cohorts at
30 days are shown.
CI ¼ conﬁdence interval; HAPR ¼ high on-aspirin treatment platelet reactivity; MI ¼ myocardial infarction;
OR ¼ odds ratio; ST ¼ stent thrombosis.
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FIGURE 2 Distribution of On-Aspirin Treatment Platelet Reactivity Measurements
Distribution of platelet function measurements in the ISAR-ASPI registry of PCI-treated
patients following loading with 500 mg of aspirin. Values obtained with the Multiplate
analyzer assay are shown as AU  min. The dotted line indicates the cut-off value for
HAPR. The gray arrow illustrates the proportion of patients with HAPR. AU ¼ aggregation
unit; HAPR ¼ high on-aspirin platelet reactivity; PCI ¼ percutaneous coronary intervention.
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867clinical outcome data for HAPR versus those for non-
HAPR patients at 1 year.
After we performed propensity-score matching,
the incidence of in-hospital bleeding events (TIMI
major and minor) differed signiﬁcantly between co-
horts (95 bleeding events [6.7%] in the HAPR cohort
vs. 67 bleeding events [4.7%] in the non-HAPR cohort;
p ¼ 0.023). According to propensity matching
analysis, the incidence of the primary outcome (inci-
dence of 1-year death or stent thrombosis) was
signiﬁcantly higher in the HAPR than in the non-
HAPR cohort (88 [6.2%] vs. 63 [4.5%] events, respec-
tively; HR: 1.44; 95% CI: 1.04 to 1.99; p ¼ 0.027).
Detailed results are provided in Online Table S3.
MULTIVARIATE ANALYSES. In a Cox proportional
hazards model with the primary endpoint as the
dependent variable and HAPR and all variables listed
in Table 1 (including troponin) as independent vari-
ables, HAPR was found to be an independent pre-
dictor of the primary outcome (adjusted HR [HRadj]:
1.46; 95% CI: 1.12 to 1.89; p ¼ 0.005).
For the primary endpoint of death or ST, the
c-statistic of the model without inclusion of HAPR
was 0.796. Adding HAPR to the model increased the
c-statistic to 0.797 (p ¼ 0.002). The IDI for the primary
endpoint was calculated, and inclusion of HAPR
in the model was associated with a signiﬁcant im-
provement of the discriminatory power of the model
regarding the prediction of death or ST at 1 year (ab-
solute IDI ¼ 0.0038; relative IDI ¼ 3.8%; p ¼ 0.018).
The NRI improved signiﬁcantly and was 19.1% after
inclusion of HAPR (95% CI: 7.5% to 30.7%; p < 0.001).
DISCUSSION
In the present ISAR-ASPI registry, we investigated the
prognostic value of on-aspirin treatment platelet ag-
gregation measurements and speciﬁcally that of HAPR
in PCI-treated patients. There are 3 key ﬁndings from
our study. First, the risk of death or ST is signiﬁcantly
higher in HAPR than in non-HAPR patients; second,
HAPR is an independent predictor for ischemic event
occurrence in PCI-treated patients receiving aspirin;
and third, knowledge of the presence or absence of
HAPR can be used to further stratify PCI-treated pa-
tients regarding their risk for death or stent throm-
bosis. In fact, performance measure with regard to
association (ORs andHRs), discrimination (c-statistics,
IDI), and reclassiﬁcation (NRI) were positive for the
biomarker (HAPR) under investigation.
With our registry data, we provide evidence for a
possible role of HAPR as a clinically useful biomarker
that could be added to the well-established bio-
markers in coronary artery disease (CAD) patients.Of note, information on the presence or absence of
HAPR increased the discriminatory power of our
multivariate Cox model, including troponin, for death
or ST prediction. Thus, knowledge of the presence of
HAPR in a PCI-treated patient receiving aspirin and
obtained at the time point of the intervention offers
prognostic information that is independent of or even
supplementary to that provided by well-established
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FIGURE 4 1-Year Incidence of Stent Thrombosis
Kaplan-Meier curves show the incidence of stent thrombosis (probable or deﬁnite) during
the 1-year follow-up period according to platelet reactivity on-aspirin treatment in HAPR
patients (red line) versus non-HAPR patients (slate line). Abbreviations as in Figure 3.
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FIGURE 3 1-Year Incidence of Death or Stent Thrombosis
Kaplan-Meier curves show the incidence of the primary endpoint (death or stent
thrombosis) during the 1-year follow-up period according to platelet reactivity
on-aspirin treatment in HAPR patients (red line) versus non-HAPR patients (slate line).
CI ¼ conﬁdence interval; HAPR ¼ high on-aspirin treatment platelet reactivity; OR ¼
odds ratio.
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868cardiovascular risk factors such as troponin level,
diabetes or other relevant comorbidities, and clinical
variables (Central Illustration). From a statistical point
of view and with regard to the performance of HAPR
as a prognostic biomarker, with the different metrics
applied (c-statistics, IDI, NRI) to assess the additive
value of HAPR in addition to clinical variables pro-
vided, statistically signiﬁcant results support the
usefulness of HAPR as a biomarker in CAD patients.
The NRI based on platelet function testing in our
study performed well in comparison to the values of
other biomarkers such as HCPR, coronary calciﬁca-
tion, and intima media thickness that have been used
to improve cardiovascular risk stratiﬁcation (25–28).
We assessed platelet reactivity in a large cohort of
7,090 PCI-treated patients who had received a dual
antiplatelet treatment regimen consisting of aspirin
and an ADP receptor blocker. Our ﬁndings concur
with those from previous, smaller studies and from
meta-analyses investigating HAPR and its role in
clinical outcome prediction (2–6,11–14,31). In contrast
to our ﬁndings, the recently published results of the
ADAPT-DES trial (12) showed no signiﬁcant associa-
tion between HAPR and ischemic events, including
death or ST. Although both our study, with 7,090
subjects, and the ADAPT-DES trial, with 8,665 sub-
jects, investigated a large cohort of PCI-treated pa-
tients including the largest population cohorts that
have been studied thus far to assess the prognostic
value of platelet function testing, the exact reason for
the discrepancy in results remains unclear. Possible
explanations include differences in study design,
which are a different time point of blood sampling
and platelet function testing (during PCI in our cohort
vs. day 1 post-PCI in ADAPT-DES), a different testing
device used (Multiplate analyzer in our cohort vs.
VerifyNow assay [Accumetrics, San Diego, California]
in ADAPT-DES), each with a distinct cut-off value to
deﬁne HAPR. By using different devices with distinct
HAPR cut-off values, the composition and size for the
populations at risk for cardiovascular events varies
widely between these 2 studies (20% in our cohort vs.
5.6% in ADAPT-DES) (12), which may in part explain
the different results observed in the 2 studies.
General issues surrounding the testing for on-
aspirin treatment platelet reactivity include the lack
of clearly deﬁned and established cut-off values to
deﬁne this phenomenon. This is in contrast to testing
the responsiveness to ADP receptor antagonists,
where consensus cut-off values are established for
the most commonly used devices for testing (1,29).
Lacking such a clear deﬁnition of HAPR, the reported
proportion of HAPR varies widely from 0.4% to 83.3%
between test methods (13–16). We chose the upper
TABLE 4 Clinical Outcome at 1 Year
Event at 1 Year
ASPI >203
(5th Quintile)
(n ¼ 1,414)
ASPI #203
(1st–4th Quintile)
(n ¼ 5,676) OR (95% CI) p Value
Primary endpoint
Death or ST deﬁnite or
ST probable
88 (6.2) 208 (3.7) 1.78 (1.39–2.27) <0.0001
Secondary endpoints
ST deﬁnite or probable 16 (1.1) 35 (0.6) 1.88 (1.05–3.37) 0.03
ST deﬁnite 11 (0.8) 27 (0.5) 1.67 (0.84–3.34) 0.15
ST probable 5 (0.4) 8 (0.1) 2.61 (0.89–7.66) 0.08
All-cause death 84 (5.9) 189 (3.3) 1.87 (1.45–2.41) <0.0001
Cardiovascular death 59 (4.2) 109 (1.9) 2.27 (1.67–3.09) <0.0001
Myocardial infarction 48 (3.4) 153 (2.7) 1.28 (0.92–1.77) 0.14
Death or MI 117 (8.3) 316 (5.6) 1.54 (1.25–1.90) <0.0001
Values are n (%). Ischemic clinical outcome data in the HAPR (ASPI >203) and non-HAPR (ASPI#203) cohorts
at 1 year are shown.
Abbreviations as in Table 3.
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869quintile of patients for deﬁning a “population at-risk”
with regard to on-aspirin treatment platelet reac-
tivity. Fixing a cut-off point at the upper quintile
of patients for HAPR was analogous to our early
investigations with regard to HCPR in clopidogrel-
treated patients undergoing PCI (30). Conﬂating pre-
sent results and results of our previous investigations
in clopidogrel-treated patients (30), it can be stated
that the upper quintile of patients must be considered
a high-risk cohort for the occurrence of ischemic
events with regard to both ADP- and AA-mediated
platelet reactivity testing results for the respective
antiplatelet agents (clopidogrel and aspirin) under
investigation. However, further studies are needed to
corroborate present results and to ﬁx HAPR cut-off
values for the different devices used for testing.
Of note, the most important factor leading to the
phenomenon of aspirin resistance or HAPR in pre-
vious studies was postulated to be simply noncom-
pliance to aspirin treatment (31,32). However, the
issue of noncompliance is overcome by the design of
our registry, as we assessed the on-aspirin treatment
platelet aggregation values after monitored IV
treatment with 500 mg of aspirin, and HAPR was
assessed at 1 time point directly before PCI. It is
important to emphasize in this context that the
value we measured cannot be considered simply as a
response marker for aspirin treatment, because
baseline (off-treatment values) are missing here,
and the determined on-treatment value is a result
of the baseline platelet reactivity level of the indi-
vidual patient and the individual response to the
administered aspirin treatment. Numerous clinical
variables and a certain inﬂammatory status are
likely to have an impact on this determined aggre-
gation value.
We investigated the prognostic value of HAPR as a
new biomarker. In multivariate analyses, we identi-
ﬁed HAPR in our registry as an independent pre-
dictor of primary outcome (death or ST) at 1 year
after PCI. Thus, for the individual patient undergoing
PCI, HAPR, assessed at a single time point at PCI,
offers prognostic information in addition to well-
established risk factors to further stratify PCI-
treated patients receiving aspirin regarding their
risk for death or ST. This leaves room for improved
clinical decision making based on HAPR assessment.
The role of HAPR testing for guidance of treatment
remains unclear and cannot be answered by our data.
The question remains whether there is a high-risk
group of patients who might beneﬁt from a tailored
antiplatelet therapy based on HAPR testing. Recent
attempts to assess the impact of an intensiﬁed aspirin
treatment on clinical outcome provide divergentresults. Although there is evidence implicating the
fact that HAPR can be overcome by higher doses of
aspirin (33), a large meta-analysis in 2002 saw no
advantage of medium or high doses compared to low
doses of aspirin for clinical outcome (34). Another
meta-analysis in 2012 comparing high- and low-dose
aspirin in patients with acute coronary syndrome
found no difference in ischemic event rates (35). In
the large-scale ARCTIC (Assessment by a Double
Randomization of a Conventional Antiplatelet Strat-
egy Versus a Monitoring-Guided Strategy for Drug-
Eluting Stent Implantation and of Treatment
Interruption Versus Continuation One Year After
Stenting) trial, designed to assess the impact of
tailored antiplatelet therapy, in case of HAPR, an
additional bolus of IV aspirin was administered
without any clinical beneﬁt (36). Another approach
was described by Frelinger et al. (37), who demon-
strated that there are ADP-dependent but cyclo-
oxygenase-1– and cyclooxygenase-2–independent
pathways in patients with residual HAPR. This
suggests that, at least in part, residual HAPR
might be overcome by additional administration
(or even prolongation) of ADP receptor antagonist
treatment (37).
Research and a better characterization of novel
biomarkers in CAD patients may improve ischemic
risk prediction and may thereby improve the out-
come of PCI-treated patients. In clinical practice, a
panel of biomarkers is used to improve individual
risk assessment (38). Testing for HAPR as a new
biomarker for PCI-treated patients under treatment
with aspirin can help to reﬁne the predictive accuracy
of such risk prediction panels in these patients.
However, further studies are needed to investigate
CENTRAL ILLUSTRATION Platelet Function Testing and Risk of
Adverse Outcomes After PCI
The predictive value of platelet function testing and the inﬂuence of HPR on adverse
outcomes in a surrounding of other cardiac biomarkers and patient’s comorbidities are
shown. HPR can be determined with respect to aspirin treatment (HAPR) and P2Y12 in-
hibitor treatment (HPPR). BNP ¼ brain natriuretic peptide; CRP ¼ C-reactive protein;
DAPT ¼ dual antiplatelet therapy; HPR ¼ high on-treatment platelet reactivity; HPPR ¼
high on-P2Y12 inhibitor platelet reactivity; PCI ¼ percutaneous coronary intervention.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Although a relationship between platelet reactivity
and clinical outcomes has been established for ther-
apy with clopidogrel in patients undergoing PCI,
correlative data regarding the clinical implications of
platelet reactivity on aspirin have been inconsistent.
This study found high platelet reactivity in patients on
aspirin at the time of PCI associated with a greater risk
of death or stent thrombosis during the ﬁrst year after
PCI.
TRANSLATIONAL OUTLOOK: Additional studies
are needed to investigate the utility of measuring
platelet reactivity in response to both aspirin and
clopidogrel in patients undergoing PCI to facilitate
individualized antiplatelet treatment regimens.
Mayer et al. J A C C V O L . 6 4 , N O . 9 , 2 0 1 4
Aspirin Treatment and Outcomes After PCI S E P T E M B E R 2 , 2 0 1 4 : 8 6 3 – 7 1
870the role of HAPR and HCPR alone and in concert with
regard to their predictive value and with regard to
their roles as possible modiﬁable cardiovascular risk
factors that can be altered by a tailored antiplatelet
treatment in patients undergoing PCI.
STUDY LIMITATIONS. First, present data are obser-
vational, with all the inherent limitations of aretrospective analysis. We did not perform an
assessment of aspirin response because baseline (off-
treatment values) data were missing in addition to
on-treatment testing. Here, we only used 1 device
(Multiplate analyzer) for platelet function testing,
and it is unknown how our ﬁndings should be
extrapolated to other platelet function assays and
clinical scenarios. Platelet reactivity on aspirin was
measured only at a single time point in the acute
phase after acute administration. These results
cannot substitute for chronic on-treatment platelet
reactivity data. For this study, drug compliance,
including compliance with antiplatelet treatment,
was not recorded on an individual basis, and we
cannot exclude the possibility that this may have
inﬂuenced the results. However, both early outcome
data at 30 days, when a high compliance rate can
be assumed, as well as 1-year outcome data pro-
vided uniform results with regard to the predictive
value of on-aspirin treatment platelet aggregation
measurements.
CONCLUSIONS
HAPR, measured at a single time point before PCI is
associated with a higher risk for death or ST during
the ﬁrst year post-PCI. Present data support the
addition of HAPR to a panel of prognostic biomarkers
in PCI-treated patients.
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